315 related articles for article (PubMed ID: 24566736)
1. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Yu H; Steeghs N; Nijenhuis CM; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2014 Apr; 53(4):305-25. PubMed ID: 24566736
[TBL] [Abstract][Full Text] [Related]
2. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Lankheet NAG; Desar IME; Mulder SF; Burger DM; Kweekel DM; van Herpen CML; van der Graaf WTA; van Erp NP
Br J Clin Pharmacol; 2017 Oct; 83(10):2195-2204. PubMed ID: 28500677
[TBL] [Abstract][Full Text] [Related]
4. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
[TBL] [Abstract][Full Text] [Related]
5. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
7. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.
Teo YL; Ho HK; Chan A
Br J Clin Pharmacol; 2015 Feb; 79(2):241-53. PubMed ID: 25125025
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacokinetic issues on cancer pharmacotherapy].
Tanigawara Y
Nihon Rinsho; 2015 Aug; 73(8):1357-63. PubMed ID: 26281690
[TBL] [Abstract][Full Text] [Related]
9. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
Terada T; Noda S; Inui K
Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
[TBL] [Abstract][Full Text] [Related]
10. How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.
Ward MB; Reuter SE; Martin JH
Clin Pharmacokinet; 2016 Oct; 55(10):1171-1177. PubMed ID: 27085335
[TBL] [Abstract][Full Text] [Related]
11. Individualized dosing of tyrosine kinase inhibitors: are we there yet?
de Wit D; Guchelaar HJ; den Hartigh J; Gelderblom H; van Erp NP
Drug Discov Today; 2015 Jan; 20(1):18-36. PubMed ID: 25245169
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic drug monitoring of tyrosine-kinase inhibitors in the treatment of chronic myelogenous leukaemia: interests and limits].
Bouchet S; Royer B; Le Guellec C; Titier K;
Therapie; 2010; 65(3):213-8. PubMed ID: 20699073
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.
Di Gion P; Kanefendt F; Lindauer A; Scheffler M; Doroshyenko O; Fuhr U; Wolf J; Jaehde U
Clin Pharmacokinet; 2011 Sep; 50(9):551-603. PubMed ID: 21827214
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
Gotta V; Widmer N; Montemurro M; Leyvraz S; Haouala A; Decosterd LA; Csajka C; Buclin T
Clin Pharmacokinet; 2012 Mar; 51(3):187-201. PubMed ID: 22339450
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology.
Janssen JM; Dorlo TPC; Steeghs N; Beijnen JH; Hanff LM; van Eijkelenburg NKA; van der Lugt J; Zwaan CM; Huitema ADR
Clin Pharmacol Ther; 2020 Sep; 108(3):494-505. PubMed ID: 32022898
[TBL] [Abstract][Full Text] [Related]
16. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.
Deng J; Shao J; Markowitz JS; An G
Pharm Res; 2014 Sep; 31(9):2237-55. PubMed ID: 24842659
[TBL] [Abstract][Full Text] [Related]
17. Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy.
Wang R; Zhong C; Zhang C; Hua M; Ma D
Curr Drug Metab; 2017; 18(3):199-206. PubMed ID: 28093990
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review.
Cardoso E; Guidi M; Blanchet B; Schneider MP; Decosterd LA; Buclin T; Csajka C; Widmer N
Ther Drug Monit; 2020 Feb; 42(1):33-44. PubMed ID: 31479043
[TBL] [Abstract][Full Text] [Related]
19. Toxicities of Receptor Tyrosine Kinase Inhibitors in Cancer Pharmacotherapy: Management with Clinical Pharmacology.
Fujita KI; Ishida H; Kubota Y; Sasaki Y
Curr Drug Metab; 2017; 18(3):186-198. PubMed ID: 28059038
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring.
Josephs DH; Fisher DS; Spicer J; Flanagan RJ
Ther Drug Monit; 2013 Oct; 35(5):562-87. PubMed ID: 24052062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]